Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PT Indofarma Tbk's EBITDA for the
three
months ended in Jun. 2026 was Rp-2,482 Mil. PT Indofarma Tbk's Revenue for the
three
months ended in Jun. 2026 was Rp25,719 Mil. Therefore, PT Indofarma Tbk's EBITDA margin for the quarter that ended in Jun. 2026 was -9.65%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Indofarma Tbk EBITDA Margin % Related Terms
PT Indofarma Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Indofarma Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:INAF vs ZTS, VTRS, NBIX: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Indofarma Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Indofarma Tbk EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Indofarma Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Indofarma Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Indofarma Tbk (ISX:INAF) has a EBITDA Margin % of -9.65% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Indofarma Tbk and its competitors.
Is PT Indofarma Tbk's EBITDA Margin % too high?
PT Indofarma Tbk's current EBITDA Margin % is -9.65%. Overall, PT Indofarma Tbk has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does PT Indofarma Tbk's EBITDA Margin % compare to ZTS and VTRS?
PT Indofarma Tbk's EBITDA Margin % of -9.65% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.11, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Indofarma Tbk and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Indofarma Tbk's current EBITDA Margin % is -9.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Indofarma Tbk stock overvalued right now?
PT Indofarma Tbk (ISX:INAF) has a current EBITDA Margin % of -9.65%. The stock's GF Value™ is Rp176.99, compared to a current price of Rp126.00 — trading 28.8% below its estimated fair value. The current EBITDA Margin % is -9.65%. PT Indofarma Tbk's overall GF Score™ is 8/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Indofarma Tbk (ISX:INAF), the current EBITDA Margin % is -9.65% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Indofarma Tbk (ISX:INAF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Indofarma Tbk stock appears to be undervalued.
The current stock price of Rp126.00 is trading 28.8% below its estimated GF Value™ of Rp176.99.
Key valuation signals for ISX:INAF:
EBITDA Margin %: -9.65%
GF Value™: Rp176.99 vs. price of Rp126.00 (28.8% below fair value)
No single metric tells the full story. See the ISX:INAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others. The Medicine business segment includes drug production, marketing distribution, and sales. The Medical Device Segment includes medical devices and other products. Company generates majority revenue from the Medicine segment. The Company classifies its distribution segments based on geographic regions into six areas, namely Java, Sumatra, Kalimantan, Sulawesi, Bali dan West Nusa Tenggara (NTB),as well as the Eastern Indonesia region.
8GF Score
Get the complete analysis for ISX:INAF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:INAF has been successfully added to your 
